Joe Volpe
Managing Director and Founding Partner @ Merck Global Health Innovation Fund
Philadelphia, United States
Joe Volpe is a funding round investor at Merck Global Health Innovation Fund in Philadelphia focused on Analytics and Health Care. Joe Volpe is the Managing Director and Founding Partner of Merck Global Health Innovation Fund. He attended the University of South Florida.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Joe Volpe invests in
Stages Joe Volpe invests in
Countries Joe Volpe invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Analytics 4 (29%)
- Health Care 4 (29%)
- Big Data 3 (21%)
- Life Science 3 (21%)
- Information Technology 3 (21%)
Stage
- Funding Round 3 (21%)
- Series B 2 (14%)
- Series C 2 (14%)
- Venture - Series Unknown 2 (14%)
- Series A 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Redica Systems uses AI and machine learning to provide Quality and Regulatory Intelligence (QRI) solutions to life sciences companies. The company's data analytics platform is designed for regulated industries to enhance quality and regulatory compliance. It connects Quality Assurance with Regulatory Surveillance to structure unstructuredcontent, delivering insights for quality and safety professionals. | $5M / May 09, 2025 | ||
| CargoSense provides data driven logistics to the healthcare industry utilizing a disruptive business model. | $8M / Series A / Jun 12, 2024 | ||
| AeroSafe Global develops and produces aerogels and related materials for temperature-sensitive shipping needs in the United States. Its products are used in various thermal insulation applications to transport biomedical, pharmaceutical, and other temperature-sensitive products. The company provides a reliable, simple, and sustainable temperaturesensitive supply chain solutions to the world’s leading biopharma companies.AeroSafe Global delivers cold-chain services for the biopharma industry that results in zero temperature excursions for every client, every product, every time. With proprietary packaging, logistics, and operational services, the company builds customized solutions that ensure the safe delivery of temperature-sensitive biopharmaceuticals. | $43M / Aug 29, 2023 | ||
| AeroSafe Global develops and produces aerogels and related materials for temperature-sensitive shipping needs in the United States. Its products are used in various thermal insulation applications to transport biomedical, pharmaceutical, and other temperature-sensitive products. The company provides a reliable, simple, and sustainable temperaturesensitive supply chain solutions to the world’s leading biopharma companies.AeroSafe Global delivers cold-chain services for the biopharma industry that results in zero temperature excursions for every client, every product, every time. With proprietary packaging, logistics, and operational services, the company builds customized solutions that ensure the safe delivery of temperature-sensitive biopharmaceuticals. | $78M / Private Equity / Aug 29, 2023 | ||
| TransVoyant is an IT company streaming and analyzing IoT and big data for the supply chain and digital supply chain. The company collects, cleanses, and constantly updates one of the repositories of real-time big data over one trillion events each day. By applying advanced machine learning algorithms to these real-time data streams, TransVoyantgives leading companies and government organizations a live global picture of their static and moving assets, as well as predictive insights that enable them to anticipate and avoid threats and disruptions resulting from a multitude of internal and external factors such as weather, port congestion, natural disasters, supplier failure, road construction, competitor behavior, and labor strikes, to name a few.TransVoyant was founded in 2011 and is headquartered in Alexandria, Virginia, United States. | $8.7M / Venture - Series Unknown / Dec 08, 2022 | ||
| AeroSafe Global develops and produces aerogels and related materials for temperature-sensitive shipping needs in the United States. Its products are used in various thermal insulation applications to transport biomedical, pharmaceutical, and other temperature-sensitive products. The company provides a reliable, simple, and sustainable temperaturesensitive supply chain solutions to the world’s leading biopharma companies.AeroSafe Global delivers cold-chain services for the biopharma industry that results in zero temperature excursions for every client, every product, every time. With proprietary packaging, logistics, and operational services, the company builds customized solutions that ensure the safe delivery of temperature-sensitive biopharmaceuticals. | $47.5M / Private Equity / Sep 10, 2020 | ||
| Healthcare professionals across the globe trust the ClearDATA HITRUST-certified cloud to safeguard their sensitive data and power their critical applications available across the major public cloud platforms. For healthcare organizations, customers receive one of the most comprehensive Business Associate Agreements (BAA) in the industry, combinedwith market-leading healthcare-exclusive security and compliance solutions, and multi-cloud expertise. ClearDATA’s innovative platform of solutions and services protects customers from data privacy risks, improves their data management, and scales their healthcare IT infrastructure, enabling the industry to focus on making healthcare better by improving healthcare delivery, every single day. | $26M / Series E / Nov 19, 2018 | ||
| Prognos Health is a leading health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables thequerying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers. | $20.5M / Series C / Nov 27, 2017 | ||
| Healthcare professionals across the globe trust the ClearDATA HITRUST-certified cloud to safeguard their sensitive data and power their critical applications available across the major public cloud platforms. For healthcare organizations, customers receive one of the most comprehensive Business Associate Agreements (BAA) in the industry, combinedwith market-leading healthcare-exclusive security and compliance solutions, and multi-cloud expertise. ClearDATA’s innovative platform of solutions and services protects customers from data privacy risks, improves their data management, and scales their healthcare IT infrastructure, enabling the industry to focus on making healthcare better by improving healthcare delivery, every single day. | $12M / Series D / Mar 30, 2017 | ||
| Healthcare professionals across the globe trust the ClearDATA HITRUST-certified cloud to safeguard their sensitive data and power their critical applications available across the major public cloud platforms. For healthcare organizations, customers receive one of the most comprehensive Business Associate Agreements (BAA) in the industry, combinedwith market-leading healthcare-exclusive security and compliance solutions, and multi-cloud expertise. ClearDATA’s innovative platform of solutions and services protects customers from data privacy risks, improves their data management, and scales their healthcare IT infrastructure, enabling the industry to focus on making healthcare better by improving healthcare delivery, every single day. | $25M / Series C / May 28, 2015 | ||
| See all 14 investments → | |||
Co-Investors
Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy. This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions.Merck GHI has $500M under management and provides growthcapital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck.With a vision that data will be the currency in healthcare, GHI invests broadly in digital health. GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation. Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.
Merck Global Health Innovation Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bill Taranto
Founder, President & General Partner
|
|||
Bill Taranto
Founder, President & General Partner
|
|||
Dave Stevenson
Managing Director
|
|||
|
Joe Volpe
Managing Director and Founding Partner
|
|||
David Rubin
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Joe Volpe invest in?
Joe Volpe invests primarily in Analytics, Health Care and Big Data startups, most often at Funding Round and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Joe Volpe?
Public channels for Joe Volpe include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Joe Volpe last invest?
The most recent investment recorded for Joe Volpe closed in May 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
